Endometrial Cancer

• EMA approval · 2026-04-23
  EMA Authorised: Jemperli (dostarlimab) — GlaxoSmithKline Trading Services Limited

  The EMA authorised dostarlimab (Jemperli) for endometrial cancer, expanding treatment options for endometrial neoplasms.

• EMA approval · 2026-04-22
  EMA Authorised: Keytruda (pembrolizumab) — Merck Sharp & Dohme B.V.

  The European Medicines Agency authorised Keytruda (pembrolizumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, ren…

• FDA approval · 2025-12-12
  FDA Approved: MEDROXYPROGESTERONE ACETATE — Supplemental Application (Prasco Laboratories)

  The FDA approved a supplemental application for Medroxyprogesterone acetate from Prasco Laboratories, resulting in labeling changes associat…

• FDA approval · 2023-06-16
  FDA Approved: CARBOPLATIN — Supplemental Application (Apotex Corp.)

  FDA approved Apotex Corp.'s supplemental application for generic carboplatin. This action permits Apotex to market a generic carboplatin for…

• FDA approval · 2023-02-09
  FDA Approved: JEMPERLI — Supplemental Application (GlaxoSmithKline LLC)

  FDA approved a supplemental application for JEMPERLI (dostarlimab) submitted by GlaxoSmithKline LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2021-04-22
  FDA Approved: JEMPERLI — Original Application (GlaxoSmithKline LLC)

  FDA approved JEMPERLI (dostarlimab) from the original application by GlaxoSmithKline for adult patients with mismatch repair deficiency recu…

• FDA approval · 2015-06-08
  FDA Approved: MEGESTROL ACETATE — Supplemental Application (Upsher-Smith Laboratories, LLC)

  FDA approved Upsher-Smith Laboratories' supplemental application for Megestrol Acetate (generic megestrol acetate) under ANDA 203139.